NO802173L - Fremgangsmaate til fremstilling av oksoalkyl-xantiner - Google Patents
Fremgangsmaate til fremstilling av oksoalkyl-xantinerInfo
- Publication number
- NO802173L NO802173L NO802173A NO802173A NO802173L NO 802173 L NO802173 L NO 802173L NO 802173 A NO802173 A NO 802173A NO 802173 A NO802173 A NO 802173A NO 802173 L NO802173 L NO 802173L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- residue
- oxoalkyl
- methyl
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 16
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 8
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- -1 5-oxohexyl residue Chemical group 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CNAULKGFZUMSBZ-UHFFFAOYSA-N 5-oxohexyl 4-methylbenzenesulfonate Chemical compound CC(=O)CCCCOS(=O)(=O)C1=CC=C(C)C=C1 CNAULKGFZUMSBZ-UHFFFAOYSA-N 0.000 description 3
- XBWPXAGHBDBODX-UHFFFAOYSA-N 8-(5-oxohexyl)-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(CCCCC(=O)C)N2 XBWPXAGHBDBODX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QVMZOLZGAZBZJS-UHFFFAOYSA-N 5-oxohexyl methanesulfonate Chemical compound CC(=O)CCCCOS(C)(=O)=O QVMZOLZGAZBZJS-UHFFFAOYSA-N 0.000 description 2
- UALYCKSVHDYQRP-UHFFFAOYSA-N 6-hydroxyhexan-2-one Chemical compound CC(=O)CCCCO UALYCKSVHDYQRP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XBEDAMVJWVPVDS-UHFFFAOYSA-N 1,3-dimethyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCCC(=O)C XBEDAMVJWVPVDS-UHFFFAOYSA-N 0.000 description 1
- YOTSOUGNZSULJR-UHFFFAOYSA-N 1-hexyl-3-methyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(CCCCC(C)=O)C=N2 YOTSOUGNZSULJR-UHFFFAOYSA-N 0.000 description 1
- DNGNNURPARKSKM-UHFFFAOYSA-N 3-ethyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione Chemical compound CCN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC DNGNNURPARKSKM-UHFFFAOYSA-N 0.000 description 1
- SCWBBXYWLYSKGK-UHFFFAOYSA-N 3-methyl-7-(5-oxohexyl)-1-propylpurine-2,6-dione Chemical compound O=C1N(CCC)C(=O)N(C)C2=C1N(CCCCC(C)=O)C=N2 SCWBBXYWLYSKGK-UHFFFAOYSA-N 0.000 description 1
- MHNVSFOURBQRPK-UHFFFAOYSA-N 3-methyl-7-propylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2CCC MHNVSFOURBQRPK-UHFFFAOYSA-N 0.000 description 1
- SOCYNBJTSAFFQI-UHFFFAOYSA-N 7-butyl-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCCC SOCYNBJTSAFFQI-UHFFFAOYSA-N 0.000 description 1
- RTYRGIMUXABCRT-UHFFFAOYSA-N 7-decyl-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCCCCCCCCC RTYRGIMUXABCRT-UHFFFAOYSA-N 0.000 description 1
- MROQSUMVRJJJLI-UHFFFAOYSA-N 7-ethyl-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CC MROQSUMVRJJJLI-UHFFFAOYSA-N 0.000 description 1
- SAEKTFXZAVNNEC-UHFFFAOYSA-N 7-hexyl-3-methyl-1-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCCCCC SAEKTFXZAVNNEC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Oppfinnelsen vedrorer en fremgangsmåte til fremstilling av oksoalkyl-xantiner hvor xantiner omsettes med alkylfulf onyloksyalkanoner eller med arylsulfonyloksyal-kanoner.
Det er kjent at man kan få (5-oksoheksyl)-xantiner av xantiner og 6-halogenheksan-2-oner. Også ved omsetning av N-(3-halogenpropyl)-xantiner med natriumacet-eddikestere, etterfølgende forsåpning og dekarboksylering ble det dannet (5-oksbheksyl)-xantiner.
Oppfinnelsens gjenstand er en fremgangsmåte til fremstilling av forbindelser med den generelle formel I
hvori R"*" og betyr en rettlinjet (w-l)r-oksoalkylrest med 4-8 karbonatomer eller (C^-C-j^-alkyl og R betyr (C-^-Cg)-alkyl, idet imidlertid minst én av restene R"<*>"eller R^ betyr en oksoalkylgruppe og idet Rp og R^ikke samtidig er metyl, når oksoalkylgruppen er en 5-oksoheksylrest. Fremgangsmåten erkarakterisert vedat man for innforing av oksoalkylresten omsetter salter av 3-alkylxantiner, 1,3- resp. 3,-7-dialkylxantiner eller av 1-oksoalkyl-3-alkyl resp. 3-alkyl-7-oksoalkyl-xantiner med alkylsulfonyloksyalkan-2-oner eller arylsulfonyloksyal-r kan-2-oner med den generelle formel
idet R betyr en alifatisk rest, fortrinnsvis en alkylrest med 1-4 C-atomer som CH^-, 0,^.^-, CF-^- eller en aro-
matisk rest som fenyl, p-tolyl, p-bromfenyl, fortrinnsvis imidlertid metyl og p-tolyl og n er 6 - 6 og fortrinnsvis 4. De enkelte utgangsstoffer kan anvendes i stbkiometriske eller også i ikke-stokiometriske mengder. Man kan anvende saltene av xåntinene, fortrinnsvis alkalisaltene, i ferdig form. Fortrinnsvis frembringer man disse salter imidlertid i reaksjonsblandingen, fortrinnsvis med kalium-karbonat.
Fremgangsmåten ifolge oppfinnelsen lar seg gjen-nomføre på teknisk enkel måte vanligvis ved en temperatur på fra 20 - 160°C, fortrinnsvis fra 60 - 140°C, eventuelt ved forhoyet eller nedsatt trykk, men vanligvis ved atmos-færetrykk. Som opplosningS" eller fordelingsmiddel egner, det seg under reaksjonsbetingelsene inerte forbindelser, som f.eks. dimetylformamid, dimetylsulfoksyd, aceton, butan-2-on eller acetonitril. Alkylsulfonyloksyalkan-2-oner og arylsulfonyloksyalkan-2-oner med formel II lar seg oppnå etter kjente metoder, fra hydroksyalkan-2-oner og halogenid-er av tilsvarende sulfonsyrer (sammenlign f.eks. Organikum, VEB Deutscher Verlag der Wissenschaften, Berlin 1976, side 683<ff.>).
De ifolge oppfinnelsen oppnådde (5-oksoheksyl)-xantiner er kjent og virker befordrende på den cerebrale og perifere gjennomblodning og/eller bronkosparmolytisk og/eller fibrinolytisk.
Eksempler
1. 1-( 5- oksoheksyl)- 3- metyl- 7- propylxantin
a) Til 34,9 g 6-hydroksyheksan-2-on og 36,4 g tri-etylamin i 500 ml metylenklorid dryppes under omroring
ved 0 - 5°C indre temperatur 36,1 g metansulfonsyreklorid. Det etteromrbres 1 time ved værelsetemperatur, utfellingen frafiltreres og filtratet vaskes noytralt og saltfritt med NaHCO^-opplbsning og vann. Etter tbrking over Na2S0^ fjer-ner man metylenkloridet ved nedsatt trykk og får 57,4 g 6-mesyloksyheksan-2-on, som er tynnsjiktkromatografisk en-hetlig (kiselgel, elueringsmiddel: dietyleter, fremkalling
iseddik/I^SO^, volumforhold 1:1). Produktet kunne anvendes direkte til innfbring av (5-oksoheksyl)-resten i xantiner, IR- spektrum ( kap.): 1710 cm'<1>(C=0), 1360 cm'1, 1180 cm'<1>(mesylat)
''• H- k. ierneresonansspektrum ( i CDCl^) :
(m, -(CH2)2-)
b) 10,4 g 3-metyl-7-propyl-xantin og 7,1 g ^CO^i 175 ml dimetylformamid oppvarmes under omrbring ved 120°C.
I lopet av en halv time tildryppes 10 g 6-mesyloksyheksan-2-on i 20 ml dimetylformamid og omrbres videre i 7 timer ved 120°C. Etter blandingens inndampning ved nedsatt trykk innstilles residuet med IN natronlut på pH 13 - 14 og ekstraheres flere ganger med metylenklorid. De samlede metylenkloridekstrakter inndampes ved nedsatt trykk og residuet oppvarmes, i 1 time i__50 ml IN saltsyre ved til-bakelbpstemperatur. Etter avkjbling innstiller man med IN natronlut på pH 13 - 14, ekstraherer flere ganger med metylenklorid, vasker de samlede metylenkloridfaser.nbytralt, tbrker og inndamper. Fra residuet fås etter rens-ning ved omkrystallisering fra isopropanol/petroleter (volumforhold 1:2) 11,5 g l-(5-oksoheksyl)-3-metyl-7-propylxantin med smeltepunkt 70 - 71°C. Fremgangsmåteproduktet er ifolge blandingssmeltepunkt, tynnsjiktkromatogram, infrarbdt- og kjerneresonansspektrene identisk med det autentiske stoff.
2. 1, 3- dimetyl- 7-( 5- oksoheksyl) xantin
a) 6- tosyloksyheksan- 2- on
Til 23,5 g 6-hydroksyheksan-2-on i 200 ml abso-lutt pyridin setter man ved -5°C på en gang 38,8 p-toluen-sulfoklorid, omrbrer 215 timer ved 0 - -5°C og tildrypper i lbpet av en halv time ved maks. 0°C 20 ml rL>0. Etter blanding med 500 g is utrystes med 3 x 250 ml metylenklorid. De samlede metylenkloridekstrakter^vaskes pyridinfrie med 2N saltsyre og noytrale med mettet NaHCO^-opplbsning og H2O, tbrkes over Na2S0^-_o.g inndampes ved nedsatt trykk.
Man får 40,8 g 6-tosyloksyheksan-2-on som kunne anvendes direkte til irmforing av (5-oksoheksyl)-resten i xantin. IR- spektrum ( kap.): 1710 cm<-1>(C=0), I36O cm"<1>, 1190 cm"1, 1180 cm'1 (tosylat)
•^ H- k. ierneresonansspektrum ( i CDCl-^):
1,9 (m, -(CH2)2-)
b) Til opplosningen av 9 g teofyllin i 175 ml dimetylformamid settes ved 120°C under omroring 7,1 g K^CO^
og i lbpet av en halv time tildryppes 14,2 g 6-tosyloksyheksan-2-on i 20 ml dimetylformamid. Etter ytterligere 5 timers omrbring ved 120°C inndamper man ved nedsatt trykk, blander residuet med 55 ml IN natronlut og ekstraherer med metylenklorid. De samlede metylenkloridfaser behandles med 30 ml IN natronlut, vaskes nbytralt med ILpO, tbrkes over Na2S0^ og inndampes. Fra residuet får man en rens-ning ved omkrystallisering fra isopropanol/petroleter (volumforhold 1:2) 9,3 g k,3-dimetyl-7-(5-oksoheksyl)-xantin av smeltepunkt 76 - 77°C.
Fremgangsmåteproduktet er ifolge blandingssmeltepunkt, tynnsjiktkromatogram,. infrarbdt spektrum og kjerneresonansspektrum identisk med det autentiske stoff.
Etter arbeidsmåten ifolge ovennevnte eksempler fremstilles fblgende (5-oksoheksyl)-xantiner og identifiser-es på samme måte som ovenfor. 3. l-propyl-3-metyl-7-(5-oksoheksyl)-xantin, smeltepunkt: 76 -78°C. 4. l-heksyl-3-metyl-7-(5-oksoheksyl)-xantin, smelte-r punkt: 35 - 38°C. 5.. l-(5-oksoheksyl)-3-metyl-7-etylxantin, smeltepunkt: 102 - 103°C 6. 1-(5-oksoheksyl)-3-metyl-7-butylxantin, smeltepunkt: 79 - 80°C. 7. 1-(5-oksoheksyl)-3-metyl-7-heksylxantin, smeltepunkt: 52°C. 8. 1-(5-oksoheksyl)-3-metyl-7-decylxantin, smeltepunkt: 64 - 66°C. 9. 1-(5-oksoheksyl)-3-etyl-7-propylxantin, smeltepunkt: 81 - 82°C. 10. l-metyl-3-t>utyl-7-(5-oksoheksyl)-xantin, n^ PO 1,5308.
Claims (7)
1. Fremgangsmåte til fremstilling av forbindelser med den generelle formel I 13
hvori R og R betyr en rettlinjet (w-l)-oks.oalkylrest med 4-8 karbonatomer eller (C^-C-^-alkyl og R betyr (C^-Cg)-alkyl, idet imidlertid minst én av restene R1 eller R^ betyr en oksoalkylgruppe og idet R^og R-^ begge ikke samtidig er metyl når oksoalkylgruppen er en 5-okso-helsylrest,karakterisertvedat salter av 3-alkylxantiner, 1,3- respk. 3,7-dialkylxantiner eller l-oksoalkyl-3-alkyl- resp. 3-alkyl-8-oksoalkylxantiner omsettes med alkylsulfonyloksyalkan-2-oner eller arylsulfo-nyloksyalkan-2-oner med den generelle formel II
hvori R betyr en alifatisk eller aromatisk rest og n betyr 2-6.
2. Fremgangsmåte ifolge krav 1,karakterisert vedat i formel II betyr R en alkylrest med 1-4 C-atomer, fortrinnsvis metyl, etyl eller trifluor-metyl.
3. Fremgangsmåte ifolge krav 1,karakterisert vedat i formel II betyr R fenyl, p-tolyl eller p-bromfenyl.
4. , Fremgangsmåte ifolge et av kravene 1-3,karakterisert vedat i formel II betyr n 4.
5. Fremgangsmåte ifolge et av kravene 1-4,karakterisert vedat xahtinene anvendes i form av deres alkalisalter.
6. ■ Fremgangsmåte ifolge et av kravene 1-5,karakterisert vedat såvel saltdannelsen av xantinene foretas in situ med. K^CO-^ som også omsetning av xantinsalter i et under reaksjonsbetingelsene overfor reaksjonsdeltagerne inert opplosnings- eller fordelings-, middel.
7. Fremgangsmåte ifolge et av kravene 1 - 5,karakterisert vedat omsetningene gjennomføres ved en temperatur fra 20 - 160°C, fortrinnsvis fra 60 - 140°C.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792929596 DE2929596A1 (de) | 1979-07-21 | 1979-07-21 | Verfahren zur herstellung von oxoalkyl-xanthinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO802173L true NO802173L (no) | 1981-01-22 |
Family
ID=6076378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO802173A NO802173L (no) | 1979-07-21 | 1980-07-18 | Fremgangsmaate til fremstilling av oksoalkyl-xantiner |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0023032A1 (no) |
| JP (1) | JPS5616486A (no) |
| AR (1) | AR227645A1 (no) |
| DE (1) | DE2929596A1 (no) |
| DK (1) | DK311580A (no) |
| ES (1) | ES8105005A1 (no) |
| FI (1) | FI802267A7 (no) |
| GR (1) | GR69741B (no) |
| NO (1) | NO802173L (no) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0157098A1 (en) * | 1980-06-21 | 1985-10-09 | Beecham Wuelfing GmbH & Co KG | Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation |
| GB8418430D0 (en) * | 1984-07-19 | 1984-08-22 | Beecham Wuelfing Gmbh & Co Kg | Treatment |
| GB8501488D0 (en) * | 1985-01-21 | 1985-02-20 | Beecham Group Plc | Treatment |
| US4851060A (en) * | 1987-08-12 | 1989-07-25 | Essex Group, Inc. | Multilayer wrapped insulated magnet wire |
| CA2030112A1 (en) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same |
| DE3942872A1 (de) * | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2336403A1 (fr) * | 1975-12-24 | 1977-07-22 | Bruneau & Cie Lab | Nouveau procede de preparation de l'acide (theophyllinyl-7)-3 propanesulfonique |
| GB1527543A (en) * | 1976-04-15 | 1978-10-04 | Degussa | Basically substituted xanthine derivatives |
| DE2714953C2 (de) * | 1977-04-02 | 1986-09-25 | Hoechst Ag, 6230 Frankfurt | Arzneimittel |
-
1979
- 1979-07-21 DE DE19792929596 patent/DE2929596A1/de not_active Withdrawn
-
1980
- 1980-01-28 GR GR62506A patent/GR69741B/el unknown
- 1980-07-15 ES ES493385A patent/ES8105005A1/es not_active Expired
- 1980-07-17 EP EP80104171A patent/EP0023032A1/de not_active Withdrawn
- 1980-07-17 FI FI802267A patent/FI802267A7/fi not_active Application Discontinuation
- 1980-07-18 NO NO802173A patent/NO802173L/no unknown
- 1980-07-18 AR AR281813A patent/AR227645A1/es active
- 1980-07-18 DK DK311580A patent/DK311580A/da unknown
- 1980-07-21 JP JP9883880A patent/JPS5616486A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GR69741B (no) | 1982-07-12 |
| FI802267A7 (fi) | 1981-01-01 |
| EP0023032A1 (de) | 1981-01-28 |
| ES493385A0 (es) | 1981-05-16 |
| DE2929596A1 (de) | 1981-02-05 |
| ES8105005A1 (es) | 1981-05-16 |
| AR227645A1 (es) | 1982-11-30 |
| DK311580A (da) | 1981-01-22 |
| JPS5616486A (en) | 1981-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO802173L (no) | Fremgangsmaate til fremstilling av oksoalkyl-xantiner | |
| NO154813B (no) | Sonde for ultralydinspeksjon av smeltet aluminium. | |
| DK153483B (da) | Fremgangsmaade til fremstilling af gamma-pyroner | |
| JP7025411B2 (ja) | インドールカルボキサミド化合物の製造方法 | |
| RU2180663C2 (ru) | Способ получения изоксазолидиндионового соединения, способ получения оксазолилэтанольного соединения (варианты), способ получения аспартатного соединения, способ получения оксазолилацетатного соединения, способ получения метансульфонатного соединения, способ получения бензилиденового соединения | |
| DE69634345T2 (de) | Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen | |
| SU747426A3 (ru) | Способ получени дитиенилалкиламинов или их солей | |
| Dali et al. | An improved synthesis of 1, 2-dehydro-N-acetyldopamine | |
| NO800899L (no) | Fremgangsmaate ved fremstilling av benzodiazepinderivater | |
| DE69732570T2 (de) | Sulfonsäureester-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE60033050T2 (de) | Acetalsulfonat-derivate, verfahren zu ihrer herstellung und verfahren zur herstellung eines styroloxid-derivats | |
| NO138978B (no) | Fremgangsmaate og apparat til strukturbehandling av kjoett, blandinger av kjoett og/eller kjoettavfall eller innmat og/eller ikke-kjoettstoffer | |
| RU2228929C2 (ru) | Способ получения 3s-3-амино-3-пиридилпропионовой кислоты и ее производных и промежуточное вещество | |
| NO140010B (no) | Analogifremgangsmaate til fremstilling av terapeutisk virksomme 6-substituerte 3-karbetoksyhydrazinopyridaziner | |
| NO150240B (no) | 4-(2`,2`,2`-trihalogenetyl)cyklobutan-1-sulfonsyresalter | |
| SU1250170A3 (ru) | Способ получени дихлоргидрата пирбутерола | |
| EP4083045A1 (en) | Novel method for synthesizing decursin derivative | |
| SU489327A3 (ru) | Способ получени четырех замещенных имидазолинов | |
| Shin et al. | Syntheses of picroroccelin diastereomers and their regioisomers | |
| KR20060060730A (ko) | 효모로부터 유래한 콜레스테롤에스터라제에 의한엔안티오퓨어 중간체의 효소적 합성 | |
| CS200213B2 (en) | Method of preparing indazole derivatives | |
| SU667126A3 (ru) | Способ получени производных оксипентановой кислоты или их солей или их рацематов, или их оптически активных антиподов | |
| SU980616A3 (ru) | Способ получени производных простых фениловых эфиров | |
| NO177855B (no) | Fremgangsmåte for fremstilling av synergistiner | |
| RU2057119C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ β -ГИДРОКСИАЛКИЛСУЛЬФАМАТОВ |